(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -1.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Biontech Se's revenue in 2025 is $2,895,894,736.On average, 6 Wall Street analysts forecast BNTX's revenue for 2025 to be $514,865,758,960, with the lowest BNTX revenue forecast at $491,880,155,499, and the highest BNTX revenue forecast at $528,437,307,780. On average, 7 Wall Street analysts forecast BNTX's revenue for 2026 to be $640,348,172,167, with the lowest BNTX revenue forecast at $431,424,310,847, and the highest BNTX revenue forecast at $876,205,396,645.
In 2027, BNTX is forecast to generate $649,956,123,218 in revenue, with the lowest revenue forecast at $481,439,025,817 and the highest revenue forecast at $792,894,732,621.